Quanterix Corp. (QTRX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$3.14

From 52W high−61.91%

Volume1.03M

Market cap$145.19M

P/E (TTM)—

P/S (TTM)0.9x

Div yield—

Key dataSep 18, 2026

Open

$3.14

From 52W high

−61.91%

Volume

1.03M

Market cap

$145.19M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.8x

P/E (TTM)

—

RSI (14)

55.0

MomentumView details →

1D Return

−1.60%

YTD Return

−52.12%

SummaryUpdated Jun 1, 2026

Quanterix Corporation (NASDAQ:QTRX) is a life sciences company founded in 2007 and headquartered in Billerica, Massachusetts. Originally incorporated as Digital Genomics, Inc., the company changed its name to Quanterix Corporation in August 2007 and went public in December 2017. Quanterix has established itself as a pioneer in ultra-sensitive protein detection technology, developing digital immunoassay platforms that enable researchers and clinicians to measure extremely low concentrations of proteins in biological samples. The company has undergone significant strategic transformation in recent years, focusing on neurology applications and building diagnostic testing capabilities, particularly for Alzheimer's disease biomarkers.

Ask drillr about Quanterix Corp. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.8x

EV/Sales

0.6x

P/S (TTM)

0.9x

P/B (TTM)

0.6x

ProfitabilityView details →

Gross Margin

42.60%

Net Margin

−80.29%

EBITDA Margin

−69.83%

ROE (TTM)

−51.90%

ROA (TTM)

−38.52%

Asset Turnover

0.45x

GrowthView details →

Revenue YoY

+23.41%

EPS YoY

−44.51%

FCF YoY

—

Revenue CAGR 3Y

+9.53%

EPS CAGR 3Y

—

EBITDA YoY

−53.11%

MomentumView details →

1D Return

−1.60%

YTD Return

−52.12%

1Y Return

−43.92%

RSI (14)

55.0

vs 50D SMA

−4.38%

vs 200D SMA

−31.54%

Capital & dividendView details →

Debt/Equity

0.14x

Current Ratio

3.40x

Quick Ratio

2.45x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.04

EPS Surprise

−153.45%

Beats (12Q)

4/12

Next Q EPS Est

−$0.43

Avg Surprise (4Q)

−51.25%

Rev Surprise

−12.20%

Financials snapshotView financials →

Revenue (TTM)

153.33M

Net Income (TTM)

−123.11M

Op. CF (TTM)

−73.21M

Next earningsNov 9, 2026 →

Latest newsMore news →

Quanterix Corporation granted inducement equity awards to newly appointed Chief Commercial Officer James Gute and two other employees in connection with the start of their employment.4d ago

Quanterix is repositioning its commercial organization and investing in diagnostics and clinical-trial capabilities following the integration of Akoya Biosciences.35d ago

Similar companies

Lucid Diagnostics Inc.LUCD Owlet, Inc.OWLT Yestar Healthcare Holdings Company Limited02393.HK Inogen, Inc.INGN Quipt Home Medical Corp.QIPT Apyx Medical CorporationAPYX Find similar companies →

Latest newsMore news →

Quanterix Corporation granted inducement equity awards to newly appointed Chief Commercial Officer James Gute and two other employees in connection with the start of their employment.4d ago Quanterix is repositioning its commercial organization and investing in diagnostics and clinical-trial capabilities following the integration of Akoya Biosciences.35d ago Quanterix Corporation announced its financial results for the second quarter ended June 30, 2026, reporting revenue below expectations due to execution challenges and market softness, while preserving cash better than planned.41d ago